Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Patents
Ranbaxy Receives Tentative Approval for Tamsulosin Capsules
July 10th, 2007
Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced that RLL has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Tamsulosin Hydrochloride Capsules, 0.4 mg. Tamsulosin HCl capsules are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Total annual market sales for Flomax(R), Tamsulosin HCl capsules were $1.1 billion (IMS - MAT: March 2007). "This tentative approval granted by the FDA under the Medicare Modernization Act (MMA) will provide Ranbaxy with an opportunity to market Tamsulosin capsules to all classes of trade at...
Source: Drug Law Weekly (2007-07-10)
|
